BR9506866A - Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a - Google Patents

Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a

Info

Publication number
BR9506866A
BR9506866A BR9506866A BR9506866A BR9506866A BR 9506866 A BR9506866 A BR 9506866A BR 9506866 A BR9506866 A BR 9506866A BR 9506866 A BR9506866 A BR 9506866A BR 9506866 A BR9506866 A BR 9506866A
Authority
BR
Brazil
Prior art keywords
cyclomarin
composition
inflammatory agent
mammals
treatment
Prior art date
Application number
BR9506866A
Other languages
English (en)
Inventor
Willian H Fencial
Robert S Jacobs
Paul R Jensen
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9506866A publication Critical patent/BR9506866A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9506866A 1994-02-18 1995-02-16 Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a BR9506866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/198,859 US5444043A (en) 1994-02-18 1994-02-18 Cyclic heptapeptide anti-inflammatory agent
PCT/US1995/001970 WO1995022339A1 (en) 1994-02-18 1995-02-16 Cyclic heptapeptide anti-inflammatory agent

Publications (1)

Publication Number Publication Date
BR9506866A true BR9506866A (pt) 1997-09-09

Family

ID=22735156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506866A BR9506866A (pt) 1994-02-18 1995-02-16 Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a

Country Status (15)

Country Link
US (2) US5444043A (pt)
EP (1) EP0744955B1 (pt)
JP (1) JPH09509318A (pt)
KR (1) KR100349485B1 (pt)
AT (1) ATE221385T1 (pt)
AU (1) AU696517B2 (pt)
BR (1) BR9506866A (pt)
CA (1) CA2181827A1 (pt)
CZ (1) CZ231896A3 (pt)
DE (1) DE69527610D1 (pt)
FI (1) FI963194A (pt)
HU (1) HU221122B1 (pt)
NO (1) NO963418L (pt)
NZ (1) NZ281823A (pt)
WO (1) WO1995022339A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444043A (en) * 1994-02-18 1995-08-22 The Regents Of The University Of California Cyclic heptapeptide anti-inflammatory agent
US5759995A (en) * 1996-09-05 1998-06-02 Phytera, Inc. Antiviral treatment
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
HUE059078T2 (hu) 2009-02-20 2022-10-28 Enhanx Biopharm Inc Glutation-alapú hatóanyagszállító rendszer
JP2012526144A (ja) 2009-05-06 2012-10-25 ラボラトリー スキン ケア インコーポレイテッド 活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2018128826A1 (en) * 2017-01-06 2018-07-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
WO2019126353A2 (en) * 2017-12-20 2019-06-27 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
CN111647050B (zh) * 2020-05-13 2021-11-09 中国科学院南海海洋研究所 一种怡莱霉素f衍生物及其在制备抗结核分枝杆菌药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) * 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) * 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
CA1172980A (en) * 1979-04-02 1984-08-21 Kenji Takemoto Pentadecapeptide and process for the preparation thereof
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4342829A (en) * 1981-05-06 1982-08-03 Eli Lilly And Company Process for preparing narasin
US4384043A (en) * 1981-09-02 1983-05-17 American Cyanamid Company Process for producing the antibiotic nosiheptide
US4409210A (en) * 1982-01-15 1983-10-11 Bristol-Myers Company Antibiotic compound
US4677071A (en) * 1982-03-25 1987-06-30 American Cyanamid Company Antibiotic agents from S. coeruleorubidus, rubidus
US4608343A (en) * 1983-06-23 1986-08-26 American Cyanamid Company Biologically pure culture of Streptomyces majorciensis Labeda
US4582639A (en) * 1984-06-18 1986-04-15 Bristol-Myers Company Antitumor antibiotic compound
US4885243A (en) * 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US5006466A (en) * 1986-11-21 1991-04-09 Merck & Co., Inc. Fermentation analogs of virginiamycin M1
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
US5217952A (en) * 1988-02-02 1993-06-08 Fujisawa Pharmaceutical Co., Ltd. Peptides WS-9326a and WS-9326b, derivatives thereof and uses thereof
US4977083A (en) * 1988-04-11 1990-12-11 Eli Lilly And Company Processes for preparing A54145 compounds
US5028590A (en) * 1988-04-11 1991-07-02 Eli Lilly And Company Derivatives of A54145 cyclic peptides
US5138036A (en) * 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5336757A (en) * 1992-02-07 1994-08-09 Harbor Branch Oceanographic Institution, Inc. Antibacterial peptide and methods of use
US5444043A (en) * 1994-02-18 1995-08-22 The Regents Of The University Of California Cyclic heptapeptide anti-inflammatory agent

Also Published As

Publication number Publication date
CZ231896A3 (en) 1997-01-15
HUT75832A (en) 1997-05-28
NO963418L (no) 1996-08-15
CA2181827A1 (en) 1995-08-24
US5593960A (en) 1997-01-14
HU221122B1 (en) 2002-08-28
FI963194A (fi) 1996-09-23
AU696517B2 (en) 1998-09-10
US5444043A (en) 1995-08-22
HU9602252D0 (en) 1996-10-28
FI963194A0 (fi) 1996-08-15
WO1995022339A1 (en) 1995-08-24
JPH09509318A (ja) 1997-09-22
DE69527610D1 (de) 2002-09-05
EP0744955A1 (en) 1996-12-04
KR100349485B1 (ko) 2002-11-18
EP0744955B1 (en) 2002-07-31
NZ281823A (en) 1997-11-24
ATE221385T1 (de) 2002-08-15
EP0744955A4 (en) 1998-12-16
AU1877395A (en) 1995-09-04

Similar Documents

Publication Publication Date Title
BR9506866A (pt) Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a
ID24398A (id) Metode untuk menghasilkan asam l-amino
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
BR0214065A (pt) Método e aparelho para a produção de um enxerto de pele e enxerto produzido dessa maneira
PT906122E (pt) Ligantes activados e metodos para os produzir e purificar
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
PT1318198E (pt) Processo para produzir um polipeptido recombinante que envolve a adicao de um inibidor de quimotripsina ao meio de cultura celular
MA23216A1 (fr) Procede de preparation et de production de lipopeptides d'actinoplanes sp .
ES2042868T3 (es) Un metodo de producir galidermina.
ES2080825T3 (es) Produccion de aminoacidos mediante bacillus metilotrofico.
ES2087109T3 (es) Procedimiento para la purificacion de una proteina antigenica de 69000 daltons a partir de bordetella pertussis.
AR008633A1 (es) Un proceso para tratar un koji de proteinas fermentado, preparado a partir de un material proteinaceo y de un carbohidrato, para la produccion de uncondimento.
DE69730497D1 (de) Antibiotika produzierende mikrobe
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
IT1250659B (it) Procedimento di purificazione di carragenine commerciali
KR920008193A (ko) 카르바스틴의 제조방법
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
DE3764559D1 (de) 4-benzyloxy-3-pyrrolin-2-on-1-yl-acetamid, dessen herstellung und verwendung.
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
BR9807144A (pt) Microorganismos com produção acrescida de ácido clavulânico
UA39895C2 (uk) Аустенітна сульфована нержавіюча сталь з покращеною здатністю до обробки
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.
AU6695896A (en) Process for regeneration of an aqueous process liquid of the amine-oxide process
KR970021040A (ko) 유기성폐기물을 이용한 유기질 비료의 제조방법
GR3026354T3 (en) Piperazinylpyridinyl water clathrates

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements